Randomized Trialhigh evidence
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
Lancet (London, England)·June 27, 2026·PMID 42218899
Why it mattersThis is the first randomized evidence that a PD-1/VEGF bispecific antibody plus chemotherapy yields a survival advantage over PD-1 inhibitor plus chemotherapy in squamous NSCLC, a population where VEGF-targeted therapy has been limited by safety concerns.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled